| DC21250 |
Lopixibat chloride |
Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT).. |
|
| DC1011 |
Lorcaserin
Featured
|
Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. |
|
| DC8644 |
Lorcaserin Hydrochloride
Featured
|
Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. |
.png)
|
| DC8645 |
Lorcaserin hydrochloride heMihydrate |
Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. |
|
| DC10254 |
L-Ornithine |
L-ornithine has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle. |
|
| DC8356 |
Losartan Carboxylic Acid
Featured
|
Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver. |
|
| DC2105 |
Lovastatin (MK-803)
Featured
|
Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent). |
|
| DC8066 |
Loxiglumide
Featured
|
Loxiglumide is a Exogenous cholecystokinin (CCK-A) receptor antagonist, stimulates calorie intake and hunger feelings in humans. |
|
| DC22338 |
Larotrectinib (LOXO-101 free base)
Featured
|
LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. |
|
| DC10867 |
LP-211
Featured
|
LP-211 is a selective and blood−brain barrier penetrant 5-HT7 receptor agonist, with a Ki of 0.58 nM, with high selectivity over 5-HT1A receptor (Ki, 188 nM) and D2 receptor (Ki, 142 nM). |
|
| DC23403 |
LP99
Featured
|
LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9. |
|
| DC20000 |
LR-90
Featured
|
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model. |
|
| DC20086 |
LRE1
Featured
|
LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase. |
|
| DC12514 |
LSD1 inhibitor 24 |
LSD1 inhibitor 24 is a novel potent, selective lysine-specific demethylase 1 (LSD1) inhibitor with IC50 of 1 nM, induces CD11b expression in THP-1 cells with EC50 of 8 nM. |
|
| DC22396 |
LSD1 inhibitor-1 |
LSD1 inhibitor-1 is a bisguanidine polyamine analogue that exhibits noncompetitive and specific LSD1 inhibition, with 14.1% remaining LSD1 activity at 10 uM in vitro. |
|
| DC23384 |
LSD1-IN-11p |
LSD1-IN-11p is a reversible LSD1 inhibitor with IC50/Kd of 79/21 nM. |
|
| DC23379 |
LSD1-IN-32 |
LSD1-IN-32 is a potent, reversible lysine specific demethylase 1 (LSD1) inhibitor with biochemical IC50 of 83 nM, Kd of 32 nM, cell EC50 of 0.67 uM. |
|
| DC8698 |
L-SelenoMethionine |
L-SelenoMethionine is a major natural food-form of selenium. |
|
| DC21249 |
LSN 3213128
Featured
|
LSN 3213128 is a novel potent, selective and orally-bioavailable antifolate with potent and specific inhibitory activity for AICARFT. |
|
| DC7878 |
LSN2814617
Featured
|
LSN2814617 is a neurotoxic positive allosteric modulator. |
|
| DC23503 |
LSP1-2111 |
LSP1-2111 is a potent, selective, and brain penetrant group III mGluRs agonist with EC50 of 2.2 and 1.7 uM for mGluR4 and mGluR6, respectively. |
|
| DC26113 |
LSP4–2022
Featured
|
LSP4–2022 is a novel potent, selective, brain-penetrant mGluR4 agonist with EC50 of 0.11 uM in cell-based assays. |
|
| DCAPI1211 |
L-Thyroxine |
L-Thyroxine |
|
| DC10072 |
LTI-291
Featured
|
LTI-291 is a Glucocerebrosidase (Gcase) activator for the treament of Parkinson's disease (PD). |
|
| DC10155 |
LTURM34 |
LTURM34 is a specific DNA-PK inhibitor with an IC50 of 0.034 μM. |
|
| DC24031 |
LTV-1 |
LTV-1 is a highly potent, cell-permeable and reversible LYP (lymphoid tyrosine phosphatase) inhibitor with IC50 of 508 nM. |
|
| DC10987 |
LTX-315 |
This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
|
| DC10988 |
LTX-401
Featured
|
LTX-401 is a novel oncolytic amino acid derivative that specifically targets the Golgi apparatus, demonstrating significant potential in cancer therapy. In vitro studies reveal that LTX-401 effectively reduces the viability of various tumor cell lines, exhibiting cytotoxic activity across a range of concentrations. Notably, it shows the highest potency against the human malignant melanoma cell line MDA-MB-435S (IC50 = 13.5 μM) and the lowest activity against the human hepatocellular carcinoma cell line HEPG2 (IC50 = 35.4 μM). For other cell lines, the IC50 values fall within a narrow range of 19-32 μM. Importantly, LTX-401 does not induce hemolysis in red blood cells at concentrations effective for cancer cell death, with hemolytic activity only observed at much higher concentrations (400 μg/mL = 1087 μM). Additionally, LTX-401 demonstrates cytotoxicity against non-malignant cell lines, including HUV-EC-C endothelial cells, HaCat keratinocytes, and MRC-5 fibroblasts, suggesting a broad but selective mechanism of action. |
|
| DC9784 |
Lu AF21934
Featured
|
Lu AF21934 is a brain-penetrating positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4),reduces the harmaline-induced hyperactivity |
|
| DC8287 |
Lubiprostone
Featured
|
Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation. |
|
